Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Evotec SE has provided a comprehensive overview of their financial and operational status for Q1 2024, reflecting mixed results influenced by the current market environment.</li><li>The report reveals a slight revenue decrease of 2% year-over-year, totaling EUR 208.8 million, attributed to a 23% decline in the Shared R&D business, overshadowed by notable advances in the Just - Evotec Biologics segment, which reported a 400% revenue increase compared to Q1 2023.</li><li>This growth primarily stems from collaborations like those with Sandoz and Department of Defense.</li></ul>

Evotec SE has provided a comprehensive overview of their financial and operational status for Q1 2024, reflecting mixed results influenced by the current market environment.The report reveals a slight revenue decrease of 2% year-over-year, totaling EUR 208.8 million, attributed to a 23% decline in the Shared R&D business, overshadowed by notable advances in the Just - Evotec Biologics segment, which reported a 400% revenue increase compared to Q1 2023.This growth primarily stems from collaborations like those with Sandoz and Department of Defense.

Evotec SE: These Are The 4 Biggest Factors Making It An Attractive Acquisition Target!

<ul><li>In assessing Evotec SE's Q1 2024 fiscal results and its potential for acquisition, a reflection on both financial metrics and strategic initiatives offers insight.</li><li>Evotec SE, amidst a challenging market environment, reported a slight revenue decrease of 2% year-over-year, totaling EUR 208.8 million in Q1 2024.</li><li>The company's primary revenue contraction stemmed from its Shared R&D business, which saw a decline of 23% compared to the same quarter in the previous year.</li></ul>

In assessing Evotec SE's Q1 2024 fiscal results and its potential for acquisition, a reflection on both financial metrics and strategic initiatives offers insight.Evotec SE, amidst a challenging market environment, reported a slight revenue decrease of 2% year-over-year, totaling EUR 208.8 million in Q1 2024.The company's primary revenue contraction stemmed from its Shared R&D business, which saw a decline of 23% compared to the same quarter in the previous year.

Evotec SE Potential Takeover: Does It Have What It Takes To Get Acquired? - Major Drivers

Index Rebal Trades & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal Trades & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The SE600 index is one of the most widely followed benchmark indices in Europe. This index is rebalanced on a quarterly basis.</li>
<li>The base date for rankings for the June 2024 index rebal event is 31st May 2024. In this insight, we take a look at the latest list of potential ADDs/DELs.</li>
<li>Currently, I see 7 ADDs and 7 DELs for the SE600 index. There are more names just outside the border requiring small price changes to get involved in index changes.</li>
</ul>


The SE600 index is one of the most widely followed benchmark indices in Europe. This index is rebalanced on a quarterly basis.
The base date for rankings for the June 2024 index rebal event is 31st May 2024. In this insight, we take a look at the latest list of potential ADDs/DELs.
Currently, I see 7 ADDs and 7 DELs for the SE600 index. There are more names just outside the border requiring small price changes to get involved in index changes.


Quiddity Leaderboard SE600 Jun 24: Potential ADDs Could Continue to Outperform Potential DELs

<ul>
<li>The SE600 index is one of the most widely followed benchmark indices in Europe. This index is rebalanced on a quarterly basis.</li>
<li>In this insight, we take a look at the potential index changes that could take place between now and the end of the June 2024 index rebal event.</li>
<li>Currently, I see 7 ADDs and 7 DELs for the SE600 index. There are more names just outside the border requiring small price changes to get involved in index changes. </li>
</ul>


The SE600 index is one of the most widely followed benchmark indices in Europe. This index is rebalanced on a quarterly basis.
In this insight, we take a look at the potential index changes that could take place between now and the end of the June 2024 index rebal event.
Currently, I see 7 ADDs and 7 DELs for the SE600 index. There are more names just outside the border requiring small price changes to get involved in index changes. 


Quiddity Leaderboard SE600 Mar 24: 7 Changes Likely; Expected ADDs Could Outperform Expected DELs

<ul>
<li>The June 2023 index changes for the DAX index family were confirmed after the close yesterday.</li>
<li>As expected, there were no changes announced for the DAX index.</li>
<li>There will be four changes for MDAX, one change for SDAX, and one change for TecDAX.</li>
</ul>


The June 2023 index changes for the DAX index family were confirmed after the close yesterday.
As expected, there were no changes announced for the DAX index.
There will be four changes for MDAX, one change for SDAX, and one change for TecDAX.


Quiddity Flow Expectations for DAX Jun 23 Rebal: Evotec Is the Main Surprise

Germany

Evotec AG offers drug research, development, and manufacturing services.  The Company offers assay development and screening and compound optimization services to pharmaceutical companies.  Evotec also develops drugs on its own for out-licensing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Evotec AG (EVT GR)

Evotec SE: These Are The 4 Biggest Factors Making It An Attractive Acquisition Target!

Evotec SE has provided a comprehensive overview of their financial and operational status for Q1 2024, reflecting mixed results influenced by the...

Baptista Research

Evotec SE Potential Takeover: Does It Have What It Takes To Get Acquired? - Major Drivers

In assessing Evotec SE's Q1 2024 fiscal results and its potential for acquisition, a reflection on both financial metrics and strategic...

Baptista Research

Quiddity Leaderboard SE600 Jun 24: Potential ADDs Could Continue to Outperform Potential DELs

The Top 10 potential ADDs have strongly outperformed the Top 7 potential DELs in the last 1-month, 3-month, and 1-year periods. I expect this trend...

Janaghan Jeyakumar, CFA

Quiddity Leaderboard SE600 Mar 24: 7 Changes Likely; Expected ADDs Could Outperform Expected DELs

My latest estimate for one-way flow is US$95mn. The expected ADDs have strong positive momentum while the expected DELs have strong negative momentum.

Janaghan Jeyakumar, CFA

Quiddity Flow Expectations for DAX Jun 23 Rebal: Evotec Is the Main Surprise

Drug discovery company Evotec AG (EVT GR) was a surprise addition to the MDAX index. The stock was previously an ineligible candidate but its...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)